Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. — VialBase Research

Summary

This preclinical study tested whether small molecule inhibition of nicotinamide N-methyltransferase (NNMT) — the enzyme target of 5-amino-1MQ — could rescue age-related deficits in muscle stem cell (muSC) function and improve skeletal muscle regeneration. The rationale is that NNMT is overexpressed with aging in skeletal muscle and is linked to impairment of the NAD+ salvage pathway, dysregulated sirtuin 1 activity, and increased muSC senescence, and that no known small molecule muSC regenerative therapeutics existed. Twenty-four-month-old mice underwent an acute local muscle injury (barium chloride injection into the tibialis anterior) and were treated with saline control, low-dose NNMTi (5 mg/kg), or high-dose NNMTi (10 mg/kg) for 1 week post-injury, or with control versus high dose for 3 weeks post-injury; 5-ethynyl-2’-deoxyuridine was given systemically to track muSC activity. Muscle stem cell proliferation and subsequent fusion were elevated in NNMTi-treated mice, supporting nearly 2-fold greater myofiber cross-sectional area and a shift in fiber size distribution toward a greater proportion of larger myofibers and fewer smaller fibers relative to controls. Prolonged treatment further augmented regeneration as measured by increasing fiber CSA, and functionally the peak torque of the tibialis anterior increased by approximately 70% versus controls. Parallel in vitro work in C2C12 myoblasts recapitulated the effect, with NNMTi promoting and enhancing myoblast differentiation alongside changes in cellular NAD+/NADH redox states. The authors frame this as the first clear evidence that NNMT inhibitors are a viable pharmacological approach to enhancing aged muscle regeneration.

Key Findings

• Design was entirely preclinical: aged (24-month-old) mice in a barium chloride muscle-injury regeneration model, plus C2C12 myoblast cell culture — no human data
• Dosing tested was 5 mg/kg (low) and 10 mg/kg (high) NNMTi versus saline control for 1 week post-injury, with a control versus high-dose comparison extended to 3 weeks post-injury
• muSC proliferation and fusion were elevated with NNMTi, supporting nearly 2-fold greater myofiber cross-sectional area and a distribution shift toward larger fibers and fewer small fibers
• Functional recovery improved: peak torque of the injured tibialis anterior rose by approximately 70% in NNMTi-treated mice compared with controls
• In vitro, NNMTi promoted and enhanced myoblast differentiation with supporting changes in cellular NAD+/NADH redox state, consistent with the proposed NAD+ salvage pathway mechanism

Relevance to 5-Amino-1MQ

This paper is the strongest mechanistic support for the muscle and healthy-aging claims attached to 5-Amino-1MQ, since it directly links NNMT inhibition to muscle stem cell reactivation, larger regenerated myofibers, and measurably better contractile function. The critical qualifier is that all of it is preclinical — aged mice and cultured myoblasts — and the model is recovery from an induced acute muscle injury in old animals, not hypertrophy or performance gain in healthy trained humans. The roughly 70% peak torque improvement and the near-2-fold cross-sectional area increase are real numbers, but they are mouse numbers in an injury-recovery context and do not translate to any predicted human effect size. There are no human trials of 5-amino-1MQ for muscle, so this study should be cited as mechanistic rationale and animal-model evidence only, never as demonstrated human benefit.

Citation

Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical pharmacology. 2019;163:481-492. doi:10.1016/j.bcp.2019.02.008.

See Also

• Parent compound: 5-Amino-1MQ